EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseases

Binhua Zou, Jiehuang Zheng, Weili He, Yan Chen, Lihong Li, Ziye Chen, Qinghe Liang, Wende Deng, Xiaojuan Li

Pharmacological Research · 2025

DOI: 10.1016/j.phrs.2025.107903 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Research, 2025. Verfasst von Binhua Zou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Anti-inflammatory and Immunomodulatory Pharmacology, Innovation Program of Drug Research on Inflammatory and Immune Diseases, NMPA Key …. Hauptthemen laut MEDLINE: Osteoclasts, Membrane Proteins, Osteoporosis, Osteogenesis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangzhou Municipal Science and Technology Project, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Excessive osteoclastogenesis disrupts the bone homeostasis, leading to bone loss and other skeletal related events in osteolysis diseases including osteoporosis and breast cancer. Although successfully improving skeletal related events, the current osteoclast inhibitors all disturb physiological bone formation with certain unacceptable severe adverse effects. After the PCSK9-siRNA marketed in 2021, increasingly siRNA drugs have been enrolled into clinical studies. Here, we observed the mRNA expression of Flot2, a raft protein, was elevated in osteoporosis. Targeted ablation of Flot2 using CRISPR/Cas9 and specific siRNA inhibited osteoclastogenesis in vitro, and ovariectomy-induced osteoporosis without affecting physiological bone mass in vivo. Mechanistically, FLOT2 deficiency disrupted its interaction with PLCγ2 and subsequently reduced osteoclastogenesis. Furthermore, Flot2-siRNA-AAV also blocked breast cancer cells-induced osteolysis in vivo. In a translation research, homo-FLOT2-siRNA suppressed osteoclastogenesis in CD14+ osteoclast precursor cells obtained from osteolytic patients. Interestingly, the abnormal protein expression of FLOT2 in blood CD14+ cells distinguished early-stage malignant breast cancer patients from people with benign breast tumors. In summary, our findings reveal Flot2-siRNA as a potential inhibitor of pathological osteoclastogenesis to treat osteolytic diseases, and identify FLOT2 protein in peripheral osteoclast precursor cells as a novel marker to facilitate early diagnosis of breast cancer, especially in premenopausal women.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoclastsMembrane ProteinsOsteoporosisOsteogenesisOsteolysisAnimalsHumansFemaleMiceRNA, Small InterferingBreast NeoplasmsMice, Inbred C57BL

Stichwörter der Autor:innen

Flot2NFATc1PLCγ2breast cancerosteoclastosteoclastogenesisosteoporosis

Substanzen

Membrane ProteinsRNA, Small Interfering

Autor:innen und Institutionen

  • Laboratory of Anti-inflammatory and Immunomodulatory Pharmacology, Innovation Program of Drug Research on Inflammatory and Immune Diseases, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong…
  • Department of Breast Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou 510630, China.

Förderung

  • Guangzhou Municipal Science and Technology Project
  • National Natural Science Foundation of China

Zitieren

APA

Zou, B., Zheng, J., He, W., Chen, Y., Li, L., Chen, Z., Liang, Q., Deng, W., & Li, X. (2025). Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseases. Pharmacological Research. https://doi.org/10.1016/j.phrs.2025.107903

Vancouver

Zou B, Zheng J, He W, Chen Y, Li L, Chen Z, et al. Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseases. Pharmacological Research. 2025. doi:10.1016/j.phrs.2025.107903

BibTeX
@article{Zou2025,
  author = {Zou, Binhua and Zheng, Jiehuang and He, Weili and Chen, Yan and Li, Lihong and Chen, Ziye and Liang, Qinghe and Deng, Wende and Li, Xiaojuan},
  title = {Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseases},
  journal = {Pharmacological Research},
  year = {2025},
  doi = {10.1016/j.phrs.2025.107903}
}
Kostenlos starten →